RxDoctor Payments Data

Orett Brown, MD

Internal Medicine · Hartford, CTNPI 1972919587

Payments from drug & device makers

$641in general payments, 2019–2025

Across 17 payments — averaging $37.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$133
  • Amgen$112
  • Lilly USA, LLC$97
  • AbbVie$93
  • Exact Sciences$69
  • Gilead$50
  • plus $88 from 3 others

What the payments were for

  • Food & beverage$62698%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson1$133
Amgen1$112
Lilly USA, LLC1$97
AbbVie(2 entities)4$93
Exact Sciences2$69
Gilead3$50
Viiv Healthcare Company2$36
Pfizer2$30
Novo Nordisk1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$35,736
Medicare patients
143
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$90,049
TrulicityDulaglutide36$74,501
TradjentaLinagliptin29$39,812
JardianceEmpagliflozin31$34,173
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$31,407
RybelsusSemaglutide14$28,510
MounjaroTirzepatide16$25,851
FarxigaDapagliflozin Propanediol21$23,355
EliquisApixaban17$18,767
LinzessLinaclotide20$16,146
JentaduetoLinagliptin/Metformin Hcl16$15,612
Tresiba Flextouch U-200Insulin Degludec15$13,471
SymbicortBudesonide/Formoterol Fumarate35$10,198
BrilintaTicagrelor13$10,111
Breo ElliptaFluticasone/Vilanterol13$7,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$22$118,56075 claims
Lilly USA, LLCTrulicity, Mounjaro$97$100,35252 claims
PfizerEliquis$30$18,76717 claims
AbbVieLinzess$93$16,14620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →